Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Clinical Cancer Research|2018Cited by 311
Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearanceDavid C. Turner, Julie A. Stone, Anna Kondic et al.|Clinical Cancer Research|2018Cited by 216
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Roxana Dronca et al.|Clinical Cancer Research|2018Cited by 38
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.Richard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Journal of Clinical Oncology|2014Cited by 35
Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.Richard W. Joseph, Richard Kefford, Tara C. Gangadhar et al.|Journal of Clinical Oncology|2015Cited by 6